TScan Therapeutics stockholders approve doubling authorized shares to 600M and elect directors

TScan Therapeutics, Inc.

Katina Dorton (19.7M for) and R. Keith Woods (23.3M for) elected as Class II directors for three-year terms.
Deloitte & Touche ratified as independent auditor for fiscal year ending Dec 31, 2026 (38.5M for).
Amendment to increase authorized voting common stock from 300M to 600M shares approved (35.9M for).
Proposal to adjourn meeting not needed; quorum and sufficient proxies already present.
Annual meeting held on May 20, 2026; no other matters submitted to vote.

item 5.03 item 5.07 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-236862
form_type: 8-K
ticker: TCRX
cik: 0001783328
company_name: TScan Therapeutics, Inc.
filed_at: 2026-05-22T20:05:44+00:00
discovered_at: 2026-05-22T20:08:00.346311+00:00
generated_at: 2026-05-22T21:12:07.552220+00:00
sec_items: ["5.03", "5.07", "9.01"]
event_type: other
sentiment: neutral
materiality_score: 0.25
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-236862
json_url: https://secwatch.observer/filing/0001193125-26-236862.json
markdown_url: https://secwatch.observer/filing/0001193125-26-236862.md
text_url: https://secwatch.observer/filing/0001193125-26-236862.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/0001193125-26-236862-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/d43301d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-236862

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.